Atlas Trials

Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma

Clinical trial NCT07657325 · RECRUITING

Trial details

NCT number
NCT07657325
Sponsor
Tianjin Medical University Second Hospital
Status
RECRUITING
Study type
OBSERVATIONAL
Renal Cell Carcinoma (RCC)
Start date
2024-04-01
Primary completion
2028-02-01
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.